Engineered chimeric antigen receptor (CAR) immune cells successfully treat lymphomas; however, they are less efficient in targeting and eliminating solid tumors. Trafficking and ensuring their survival in the tumor microenvironment until all cancer cells are eliminated remains a challenge. In this webinar, experts will discuss advances that bring CAR therapy for solid tumors one step closer to reality.

Topics to be covered

• Engineering off-the-shelf CAR immune cells
• Improving CAR T therapy efficacy with the gut microbiome

Speaker Information: